Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T. The role of genetic markers in the management of prostate cancer. Eur Urol. 2012;62(4):577–87.
Article
CAS
PubMed
Google Scholar
Pecuchet N, Fournier LS, Oudard S. New insights into the management of renal cell cancer. Oncology. 2013;84(1):22–31.
Article
CAS
PubMed
Google Scholar
Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.
Article
PubMed
PubMed Central
Google Scholar
Julka PK, Doval DC, Gupta S, Rath GK. Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines. Br J Radiol. 2008;81(966):444–9.
Article
CAS
PubMed
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Article
CAS
PubMed
Google Scholar
Leon L, Garcia-Figueiras R, Suarez C, Arjonilla A, Puente J, Vargas B, Mendez Vidal MJ, Sebastia C. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Target Oncol. 2014;9(1):9–24.
Article
PubMed
Google Scholar
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(1):289–96.
Article
CAS
Google Scholar
Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(3):454–63.
Article
Google Scholar
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(34):5794–9.
Article
CAS
Google Scholar
Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urology. 2012;53(4):217–28.
Article
Google Scholar
Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy. 2012;58(6):468–74.
Article
CAS
PubMed
Google Scholar
Ye D, Eto M, Chung JS, Kimura G, Chang WC, Chang YH, Pang ST, Lee JL, Niu Y, Gurney H, et al. Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia. Clin Genitourin Cancer. 2014;12(4):225–33.
Article
PubMed
Google Scholar
Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T, De Santis M. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol. 2012;29(3):1896–907.
Article
CAS
PubMed
Google Scholar
Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Annals Oncol. 2007;18(2):249–55.
Article
CAS
Google Scholar
De Lichtenberg TH, Hermann GG, Rorth M, Hojer Larsen MJ, Mansourvar Z, Holm ML, Scheike T. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre. Scand J Urol Nephrol. 2014;48(4):379–86.
Google Scholar
Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. Annals Oncol. 2012;23(2):395–401.
Article
CAS
Google Scholar
Eichelberg C, Vervenne WL, De Santis M, Fischer Von Weikersthal L, Goebell PJ, Lerchenmuller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol. 2015;68(5):837–47.
Article
CAS
PubMed
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(22):3584–90.
Article
CAS
Google Scholar
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.
Article
CAS
PubMed
Google Scholar
Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(8):1280–9.
Article
CAS
Google Scholar
Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–96.
Article
CAS
PubMed
Google Scholar
Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol. 2015;33(8):339. e339-339 e315.
Article
PubMed
Google Scholar
Shinohara N, Abe T. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. Int J Urol. 2015;22(10):888–97.
Article
PubMed
Google Scholar
Procopio G, Testa I, Verzoni E, Iacovelli R, Grassi P, Galli G, De Braud F, Saravia D, Salvioni R. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. Oncology. 2015;88(3):133–8.
Article
CAS
PubMed
Google Scholar
Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10(4):517–22.
Article
PubMed
Google Scholar
Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol. 2013;43(6):616–28.
Article
PubMed
PubMed Central
Google Scholar
Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):760–7.
Article
CAS
Google Scholar
Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014;65(6):1086–92.
Article
PubMed
Google Scholar
Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Tumori. 2007;93(1):68–74.
PubMed
Google Scholar
Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48(2):202–8.
Article
CAS
PubMed
Google Scholar
Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, Luca Burgio S, Berardi R, Muzzonigro G, Cortesi E, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;109(7):1755–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kwon WA, Cho IC, Yu A, Nam BH, Joung JY, Seo HK, Lee KH, Chung J. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. Ann Surg Oncol. 2013;20(13):4397–40.
Article
PubMed
Google Scholar